CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Denosumab (Drug Plan Submission)

Last Updated: March 10, 2015
Result type: Reports
Project Number: SR0414-000
Product Line: Reimbursement Review

Generic Name: Denosumab (Drug Plan Submission)

Brand Name: Prolia

Manufacturer: Amgen Canada

Therapeutic Area: Osteoporosis, men

Indications: Osteoporosis, men

Submission Type: Drug Plan Initiated

Project Status: Complete

Date Recommendation Issued: September 21, 2015

Recommendation Type: List with clinical criteria and/or conditions